A Phase 3, Randomised, Investigator-blind, Active-controlled, Parallel Group, Multicentre Trial Comparing the Efficacy and Safety of 4-weeks Treatment With LEO 90100 and Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis

This study is conducted to assess the efficacy and safety of LEO 90100 when used on the body for the treatment of stable plaque psoriasis in native adult Chinese subjects, compared to Daivobet® ointment.

开始日期2023-06-21

申办/合作机构

Leo Pharma, Inc.

CTR20223222 / Active, not recruiting临床3期

一项在中国稳定性斑块状银屑病成人受试者中比较LEO 90100和得肤宝 ®软膏治疗4周的有效性和安全性的III期、随机、研究者设盲、活性药物对照、平行分组、多中心试验

主要目的：评价LEO 90100与得肤宝®软膏相比对稳定性斑块状银屑病严重程度和范围的有效性。次要目的：评价LEO 90100与得肤宝®软膏相比治疗稳定性斑块状银屑病的安全性。

开始日期2023-06-21

申办/合作机构

LEO Laboratories Ltd.

[+2]

DRKS00031464 / RecruitingN/A

An international, prospective, observational cohort study to assess patient treatment satisfaction, patient-reported outcomes, effectiveness, and safety of a fixed-dose combination of Calcipotriene/Betamethasone Dipropionate PAD cream in the treatment of mild-to-moderate plaque psoriasis of the scalp in adults (PRO-SCALP) - PRO-SCALP Study

开始日期2023-06-13

申办/合作机构

Almirall SA

100 项与倍他米松二丙酸酯/卡泊三醇相关的临床结果

登录后查看更多信息

100 项与倍他米松二丙酸酯/卡泊三醇相关的转化医学

登录后查看更多信息

100 项与倍他米松二丙酸酯/卡泊三醇相关的专利（医药）

登录后查看更多信息

项与倍他米松二丙酸酯/卡泊三醇相关的文献（医药）

2023-12-31·The Journal of dermatological treatment

Potential biomarkers for psoriasis topical treatment by in-depth serum proteomics

Article

作者: Yu, Xiaobo ; Deng, Hao ; Zhang, Xiaomei ; Lu, Chuanjian ; Yu, Jingjie ; Yao, Danni ; Cui, Jingwen ; Deng, Jingwen ; Ye, Shuyan ; Han, Ling ; Yan, Yuhong

BACKGROUND:

Psoriasis is a chronic skin disease, and topical sequential therapy with a combination of calcipotriol and calcipotriol betamethasone is currently approved topical treatment. However, the exact mechanism by which this treatment regimen relieves psoriasis is unknown.

METHOD:

We assembled a cohort of 65 psoriasis patients and divided post-treatment cohort into responder group and non-responder group according to the Psoriasis Area Severity Index (PASI) score after 12-week treatment. We measured the expression levels of proteins in collected 130 serum samples using our in-depth proteomics platform with a data-independent acquisition mass spectrometer and antibody microarray. We performed bioinformatics analyses of the biologic processes and signaling pathways that were changed in the responder group and constructed a proteomics landscape of psoriasis pathogenesis response to treatment. We then validated the biomarkers of disease severity in an independent cohort of 88 samples using an enzyme-linked immunosorbent assay.

RESULTS:

We first identified 174 differentially expressed proteins (DEPs) for comparative analysis of proteins between responders and non-responders at baseline (p < 0.05). Then pathway analysis showed that the responders focused more on signaling molecules and interaction, complement and coagulation cascades, whereas the non-responders more on signal transduction and IL-17 signaling pathways. We further identified four candidate biomarkers (COLEC11, C1QA, BNC2, ITIH4) response to treatment. We also found 125 DEPs (p < 0.05) after treatment compared with before treatment in responder group. Pathway analysis showed an enrichment in pathways related to complement and coagulation cascades, phagosome, ECM-receptor interaction, cholesterol metabolism, vitamin digestion and absorption. CD14 was validated as potential biomarkers for the disease severity of psoriasis and treatment targets.

CONCLUSION:

In this work, we analyzed the response to topical sequential therapy and finally identified four biomarkers. Additionally, we found that topical sequential therapy may alleviate psoriasis by regulating lipid metabolism and modulating the immune response by affecting the complement activation process.

2023-11-01·European review for medical and pharmacological sciences

The role of the foam formulation in improving psoriasis treatment acceptability: a real-life experience and a literature review.

Review

作者: Papa, S ; Gasparini, S ; Martella, A ; Giovene, G L

BACKGROUND:

Topical therapies represent the first-line treatment for mild-to-moderate psoriasis. Among various topical options, the fixed-dose combination of calcipotriene (Cal) and betamethasone dipropionate (BD) foam (Enstilar®, LEO Pharma, Ballerup, Denmark) showed superior efficacy to Cal and BD monotherapy and ointment and gel formulations. In addition, the Cal/BD foam is the only topical treatment allowed for either reactive treatment of relapse or twice-weekly maintenance use. Since treatment acceptability is crucial to optimize adherence, this paper presents a case series from a multicenter experience using the Cal/BD foam, to further characterize the use of this therapeutic approach. In addition, a narrative review of studies evaluating the acceptability of the Cal/BD foam, even compared with other formulations, is provided.

CASE SERIES:

The case series involved adult patients with mild-to-moderate psoriasis treated with the Cal/BD foam from October 2021 to June 2022. A clinical and dermoscopic evaluation of plaques was provided for all patients. Data from the clinical practice report complete clinical resolution of plaques in most patients after 4 weeks of active treatment with the Cal/BD foam, and the dermoscopic clearance after a maximum of 8 weeks. Full adherence to treatment was also reported. Literature evidence suggests that the Cal/BD foam is easy to apply and presents high cosmetic acceptance, rapid onset of action, high efficacy, optimal safety, and a high patient preference. The high satisfaction obtained with Cal/BD foam suggests that this formulation is better accepted than others.

CONCLUSIONS:

The Cal/BD foam represents a valuable approach for managing mild-to-moderate psoriasis, both in short and long-term treatment.

2023-04-01·Journal of cosmetic dermatology

Comparative evaluation of the efficacy of topical tacrolimus 0.03% and topical calcipotriol 0.005% mixed with betamethasone dipropionate versus topical clobetasol 0.05% in treatment of alopecia areata: A clinical and trichoscopic study

Article

作者: Radwan, Mona ; Nassar, Amany ; Albalat, Waleed ; Elradi, Mona

Abstract:

Background:

Alopecia areata (AA) is a common non‐scarring hair loss disorder that affects children and adults with a great psychological burden because of its recurrent and sometimes treatment‐refractory nature.

Objective:

To compare the efficacy of topical calcineurin inhibitor, topical potent steroid combined with vitamin D analogue versus topical superpotent steroid in treatment of localized AA.

Patients and Methods:

Sixty subjects with chronic (>1 year) localized (SALT score < 25%) AA, confirmed clinically and dermoscopically, were randomized into three groups. Group I used topical 0.03% tacrolimus (Tarolimus®), group II used topical potent steroid combined with vitamin D analogue (Daivobet®). and group III used topical superpotent steroid (Dermovate®). All patients continued a daily therapy for three successive months and were followed up for three other months. Assessment was done using PULL test, SALT score, and dermoscopic comparison before and after therapy.

Results:

Group II showed comparable statistical results to group III with lower values in a non‐statistically significant way. Group I achieved the least improvement among all groups.

Conclusion:

Combined vitamin D analogues with potent steroid appears to be a more convenient treatment for localized AA than superpotent steroids because of less side effects and comparable efficacy. Tacrolimus needs further research or formula customization to be used as a topical therapy for AA.

项与倍他米松二丙酸酯/卡泊三醇相关的新闻（医药）

2024-05-08

·美通社

利奥制药宣布Enstilar®（LEO90100）在中国开展的III期临床试验的Topline结果显示，Enstilar®在患有稳定性斑块状银屑病的中国成人受试者中表现出优效性

Enstilar ® （LEO 90100）在主要终点和双重次要终点中均表现出优于得肤宝 ® （卡泊三醇倍他米松软膏）的优效性，这表明其在降低稳定性斑块状银屑病的严重程度和范围方面具有更好的疗效。总体而言，得肤宝 ® （卡泊三醇倍他米松软膏）和Enstilar ® 均具有良好的耐受性。安全性特征与之前的试验结果一致，并且符合预期，未发现新的安全性问题。该临床试验是利奥制药扩大在中国业务的承诺，通过提供额外的治疗选择为中国银屑病患者带来根本性的改变。 Enstilar ® 是一款以得肤宝 ® （卡泊三醇倍他米松软膏）活性成分为基础的独特的皮肤泡沫制剂，目前是银屑病外用药领域的全球市场领先者。丹麦巴勒鲁普 2024年5月8日 /美通社/ -- 利奥制药作为医学皮肤科的全球领导者，于5月7日宣布了Enstilar ® 在中国稳定性斑块状银屑病成人患者中开展的III期临床试验的积极结果。该临床试验是一项在中国稳定性斑块状银屑病成人受试者中比较Enstilar ® （LEO90100）和得肤宝 ® （卡泊三醇倍他米松软膏）（每日使用一次，为期4周）的有效性和安全性的多中心、随机、研究者设盲、活性药物对照、平行分组的III期临床试验。在中国的39个研究中心共计招募了604名患者。 1 该研究的主要目的是评估Enstilar ® （LEO 90100）相较于得肤宝 ® （卡泊三醇倍他米松软膏）在治疗稳定性斑块状银屑病的有效性。次要目的是评估治疗的安全性。探索性目的包括评估健康相关生活质量。 1 Topline结果表明，Enstilar ® 在主要终点上相较于得肤宝 ® （卡泊三醇倍他米松软膏）表现出优效性。利奥中国总经理殷晓峰表示：" 基于这些令人鼓舞的临床研究成果，我们很期待能够在未来向中国监管当局递交 Enstilar ® 的上市申请。同时，我也非常兴奋，除了利奥中国现有的产品组合外，我们现在有机会为中国患者带来一种新的治疗选择。" 该研究的主要研究者、北京大学人民医院张建中教授表示： "在中国，大约有 700 万银屑病患者 2 。外用药物是银屑病的基本治疗，适合大多数患者。作为本研究的主要研究者，我很高兴看到 Enstilar ® 在中国开展的 III 期临床试验中达到了其主要和次要终点，表现出优于得肤宝 ® 的疗效，且具有良好耐受性的安全性。期待在不久的将来能和同道们分享该项高质量研究的详细数据，希望 Enstilar ® 能尽早用于中国银屑病患者。" 双品牌试验彰显利奥制药在中国的实力 Enstilar ® -- 一种含卡泊三醇/倍他米松的皮肤泡沫剂 -- 是得肤宝 ® （卡泊三醇倍他米松软膏）的改良剂型，得肤宝 ® （卡泊三醇倍他米松软膏）是目前治疗稳定性斑块状银屑病中国成人患者的标准治疗选择之一。 3 该试验提前四个月完成了患者招募，体现了利奥制药在中国日益增长的业务和活动的承诺。利奥制药PSIO全球执行副总裁Becki Morison表示： " 利奥制药在中国的业务发展迎来了振奋人心的进展。我们不仅看到了结果的优效性，还看到了两种组合产品的疗效和良好耐受性。中国是利奥制药的关键市场之一 — 中国的皮肤科领域快速发展，得益于中国团队的出色表现，我们的收入稳步增长。此次试验是利奥制药利用我们深厚的皮肤病学知识来拓展我们在中国的创新和核心产品组合的绝佳例证。" 基于这些结果，利奥制药将着手准备向中国监管当局递交Enstilar ® 的上市申请。 Enstilar ® 中国试验的详细结果将在稍后提交，用于科学报告和出版物。有关Enstilar ® 临床试验（NCT05919082）的更多信息，请访问 clinicaltrials.gov 。 * 本文涉及的 Enstilar ® 尚未在中国获批 " 关于 Enstilar ® Enstilar ® 是一款泡沫制剂气雾剂，含有卡泊三醇一水合物（50mcg/g）和二丙酸倍他米松（0.5mg/g）。在欧盟，其适用于治疗成人寻常型银屑病。使用Enstilar ® 每日一次治疗4周后有治疗响应的患者适合接受长期维持治疗。 3-6 关于银屑病银屑病是一种慢性炎症性皮肤病，经常伴有多种身体和/或心理共病（存在一种或多种其他疾病），例如银屑病关节炎、糖尿病、心血管疾病和抑郁症。 7 参考文献 ClinicalTrials.gov: A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis | ClinicalTrials.gov (Accessed May 2024 ) Xiaolan Ding et al. Prevalence of psoriasis in China : A population-based study in six cities. European Journal of dermatology: EJD 22(5):663-7 中国银屑病诊疗指南（2023版） Koo J, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris—A randomized phase II study. Journal of Dermatological Treatment. 2016;27(2):120-127. Leonardi C, et al. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris—a Randomized Phase III Study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468-1477. Lebwohl M, et al. Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study. J Clin Aesthet Dermatol. 2016;9(2):34-41. National Psoriasis Foundation. Comorbidities associatied with psoriatic disease. Available www.psoriasis.org/about-psoriasis/related-conditions . Last accessed May 2024 关于利奥制药利奥制药是一家引领标准治疗，惠及皮肤疾病患者及其家庭和社会的全球公司。利奥制药成立于1908年，大部分股权隶属于LEO基金会，数十年来一直致力于研发，以推动皮肤病科学的发展。如今，利奥制药为不同严重程度的疾病提供了广泛的治疗方案。利奥制药总部位于丹麦，拥有全球员工4300名，为全球数千万患者提供服务。2023年，该公司的净销售额为114亿丹麦克朗。在中国，利奥制药专注于银屑病、特应性皮炎和皮肤感染3大疾病领域，是相关疾病领域的市场领导者，通过有竞争力的产品和服务来提高人们的生活质量。

临床3期临床结果临床成功

2024-04-22

·药渡Daily

华东医药正在悄然称王

又一家药企总营收首次突破400亿元。近日，华东医药发布最新年报，2023年全年，其总营收406.24亿元，同比增长7.71%；净利润28.39亿元，增长13.59%；扣非归母净利润27.37亿元，增长13.55%。其中，医药工业实现销售收入122.17亿元，增长9.45%；净利润23.30亿元，增长9.63%。华东医药发展路径颇有复星医药的影子，但作为同等量级的BigPharma，华东医药在没有新冠业务的羁绊下，表现得更加凶猛，不仅在“减重”领域一路狂飙、在“医美”路上横冲直撞，而且在外延式投资并购方面，更是出手大方，豪掷千金，俨然一副称王称霸的姿态。01津贴热点虽然华东医药十分凶猛，但在战略布局的谋划上，并非鲁莽。站在当下回顾，诸多药企均栽在了新冠相关产品的布局上，投入巨大的新冠项目在“乙类乙管”之后，迅速成为了负资产。但我们看到，近年来紧贴时代发展潮流的华东医药，却在新冠相关布局上十分谨慎。这是谋略上的坚定，亦或仅仅只是迷雾时代的踌躇？真正的原因不得而知，但从华东医药的谋篇布局上，或许可以猜测一二。紧贴时代热点，是近年来华东医药最显著的发展特征。2021年“医美”赛道大爆发，我们看到了华东医药打造了中国最全“医美”布局；GLP-1火热起来以后，正巧落在了华东医药的主打领域，因此我们也看到了中国最全面的GLP-1布局；ADC火爆全球，我们看到了华东医药活跃的身影；自免赛道正在预热，我们又惊喜地发现，华东医药早就置身其中。热点在哪里，哪里就有华东医药活跃的身影。核心业务降糖药的研发方面，华东医药已建立了涵盖口服、注射剂等多种剂型包括长效、单靶点和多靶点全球创新药和生物类似药相结合的6款在研及已上市产品管线。特别是在GLP-1方面，华东医药自主研发的口服小分子GLP-1受体激动剂HDM1002糖尿病适应症已于2023年5月获中美双IND批准；超重或肥胖人群的体重管理适应症的中国IND申请已于2023年9月获得批准。目前该产品已启动II期临床研究。自主研发的GLP-1R/GIPR双靶点长效多肽类激动剂HDM1005用于超重或肥胖人群的体重管理、2型糖尿病2个适应症的中国IND申请已于2024年3月获得批准，正在中国进行Ia期临床。控股子公司道尔生物在研的FGF21R/GCGR/GLP-1R靶点的多重激动剂DR10624已完成中国、新西兰的I期研究，目前正在新西兰开展肥胖合并高甘油三酯血症的Ib/IIa期临床试验。此外，华东医药的利拉鲁肽糖尿病、减重适应症均已获批，德谷胰岛素目前已完成III期临床入组，预计2024年Q4获得主要终点数据。华东医药降糖药领域研发管线来源：年报肿瘤领域研发方面，华东医药建立了涵盖靶向小分子化药、ADC、抗体、PROTAC等超过30项肿瘤创新药产品。从美国ImmunoGen引进的全球首创ADC新药索米妥昔单抗注射液（ELAHERE，研发代码：IMGN853、HDM2002）的中国上市许可申请于2023年10月获得受理，适应症为治疗既往接受过1-3线系统性治疗的叶酸受体α（FRα）阳性的铂类耐药的上皮性卵巢癌、输卵管癌或原发性腹膜癌成年患者。1类新药迈华替尼于2023年5月被纳入突破性治疗品种，用于EGFR罕见突变的晚期非小细胞肺癌。此外，迈华替尼用于EGFR敏感突变的晚期非小细胞肺癌III期临床试验已成功达到主要终点，预计于2024年递交一线EGFR敏感突变的上市申请。首个自主研发ADC项目HDM2005，拟开发用于晚期实体瘤和血液瘤治疗，已于2024年3月递交中国IND申请获受理；首个全自研的HPK-1 PROTAC（造血祖激酶1蛋白降解靶向嵌合体）药物HDM2006已进入IND研究阶段，拟用于晚期实体瘤和血液瘤的单药和联用治疗，预计于2024年底递交IND申请。华东医药肿瘤研发管线来源：年报然而，华东医药最大的收获应该是在自免领域。在这个即将崛起的赛道，华东医药通过注资荃信生物投身其中，填补了自免领域的短板。02自免布局今年3月，荃信生物正式登陆港交所。虽是初登资本市场，但江湖上早有它的传说。在国内专注自免赛道的Biotech并不算多，荃信生物凭借丰富的管线占有着极大的份量。在研管线中包含两个核心产品QX002N及QX005N，以及七个其他候选药物；涉及的靶点包括IL-17A、IL-33、TSLP、IFNAR1等，涵盖了自身免疫和过敏性疾病的四个主要领域，即皮肤、风湿、呼吸道及消化道疾病；适应症包括银屑病、特应性皮炎、系统性红斑狼疮、中重度哮喘等等。华东医药与荃信生物的渊源，可追溯至上世纪90年代。荃信生物创始人为裘霁宛，在1993年毕业后，加入九源基因负责新药研发，而九源基因正是华东医药前董事长李邦良所创建。在九源基因工作11年后，裘霁宛离职创业，并得到华东医药的鼎力相助。在荃信生物2020年的B+轮融资中，华东医药以3.7亿元高调注资，一跃成为荃信生物第二大股东。上市之前，华东医药依然是荃信生物的第二大股东，持续比例高达17.09%。除股权投资外，华东医药还是荃信生物重要的合作伙伴。荃信生物临床进度最快的QX001S的国内商业化权益就被授权给了华东医药，合计从华东医药收取5000万美元付款，以及未来QX001S在国内一半的税前利润。QX001S是首个在中国提交上市申请的国产乌司奴单抗生物类似药，且可能成为首个获批的乌司奴单抗生物类似药。乌司奴单抗于2009年获得美国FDA批准，是针对性抑制IL-23及IL-12路径的首款生物疗法，是治疗银屑病的主要疗法之一。在针对银屑病的III期临床试验中，QX001S显示出与乌司奴单抗相当的临床疗效、安全性、免疫原性及PK特性。QX001S已于2023年7月在中国提交上市申请，预计2024年第四季度获批。荃信生物股权结构中华东医药占比情况来源：荃信生物招股书除了注资荃信生物，华东医药在自免疾病领域已拥有生物药和小分子创新产品10余款。从美国Kiniksa引进的全球创新产品利纳西普（ARCALYST），在国内被列入《临床急需境外新药名单（第一批）》，用于治疗冷吡啉相关的周期性综合征（CAPS）；CAPS适应症的中国上市许可申请于2023年11月获得受理；2024年3月，利纳西普治疗复发性心包炎适应症的中国上市许可申请也获得受理。用于治疗系统性红斑狼疮的创新药HDM3002（PRV-3279）的IND申请已于2023年4月获批，正式加入IIa期MRCT试验（PREVAIL-2）。2023年引入的一系列皮肤疾病适应症的外用制剂，包括从美国Arcutis引进的治疗斑块状银屑病、特应性皮炎、脂溢性皮炎和头皮及身体银屑病Zoryve（罗氟司特乳膏剂和罗氟司特泡沫剂）；从MC2引进的治疗斑块状银屑病Wynzora乳膏，相关的临床注册工作都在积极推进中。华东医药自免在研管线来源：年报03结语在BD方面，华东医药依然延续凶猛的外延式发展策略，引进了一系列十分具有潜质的成熟产品，包括科济药业的泽沃基奥仑赛、罗氟司特乳膏剂、Wynzora乳膏和塞纳帕利等，在医美领域更是横扫市面上各类型肉毒素产品，成为当前中国医美管线最全药企。从华东医药的这一系列布局上，减重、ADC、自免、医美将成为未来华东医药“四驾马车”，特别是在消费医疗方面，目前看来，国内几无对手。后续发展如何，药渡还将持续关注。参考资料华东医药官网、年报、公告等《荃信生物IPO：华东“影子股”，自免“填坑人”》，医曜，2024-03-18

财报抗体药物偶联物临床申请临床1期生物类似药

2024-03-14

·PRNewswire

Psoriasis in America - Insights into Psoriasis Patient Demographics, Quality of Life, Information-seeking Behaviors, HCP Engagement and Treatment Experiences

DUBLIN, March 14, 2024 /PRNewswire/ -- The "Psoriasis in America 2023: Understanding the Psoriasis Patient Experience" report has been added to ResearchAndMarkets.com's offering. Approximately 7.5 million people in the United States have psoriasis. This Psoriasis in America report provides a comprehensive look at life for those living with psoriasis. Using detailed quantitative data, it gives a full picture of the psoriasis patient experience - from symptoms to treatment to HCP relationships to quality of life - so you can make informed, strategic decisions, identify opportunities, and understand potential challenges. The report offers an in-depth look at the psoriasis patient experience. This large-scale, patient-reported data leverages vital quantitative insights essential to understanding key touchpoints in the psoriasis patient journey, including condition management, HCP engagement, quality of life, treatment experience and satisfaction, and much more. This report lifts the curtain on life with psoriasis, giving stakeholders an actionable look at the behaviors, attitudes, perceptions, needs, and experiences of people living with the condition. Data can be used to inform strategic decisions, including product communications, competitive assessments, concept development, landscape analyses, patient journey overlays, and forecasting inputs. This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost - please see the report following purchase for more information. The analyst reaches millions of people through its portfolio of 45+ condition-specific online health communities - including PlaquePsoriasis.com - to provide information, connection, and support to patients and caregivers in the U.S. This report includes a deep-dive into: Psoriasis patient demographics Age, gender, ethnicity, marital status, children, employment status, income, location, insurance, and other health conditions Impact of psoriasis on quality of life Severity, impact on quality of life, symptoms experienced, and what patients wish others better understood Information-seeking behaviors Information sources used, plus topics of interest HCP engagement Primary HCP seen for condition, satisfaction with HCP, and discussion about brands aware of/not used Psoriasis treatment awareness and experiences Aided awareness of specific treatments, treatment experience, satisfaction with current treatments, perceived control with current treatment plan, and interest/participation in clinical trials Key questions answered in this report: To what extent do people say psoriasis impacts their overall quality of life? What's the average number of flares in the past year? What do patients wish others understood about psoriasis? What percentage of patients see a specialist for psoriasis treatment? What treatments have the highest aided brand awareness among patients? What percentage of patients use a biologic? How many patients feel their psoriasis is well-controlled on their current treatment plan? What percentage of patients are likely to switch or add new treatments in the next six months? What medications have patients discussed with their HCP? What are the top online resources people with psoriasis use to find information? What kinds of content and information do patients search for? What percentage of patients search for information on treatment options? Methodology Psoriasis in America consists of: A 20-minute online quantitative survey, covering demographics, comorbidities, quality of life/impact, HCP interactions, as well as treatment awareness, experiences, and discussions Qualitative patient insights from open-ended responses Additional details: Fielded: January 16, 2023 to April 14, 2023 Convenience sample of 490 respondents diagnosed with psoriasis Respondents are age 18+, living in the U.S., and are recruited from proprietary online health communities and recruiting partners Key Topics Covered: Respondent Demographics Research Highlights Condition Status and Quality of Life Severity and Exacerbations Symptoms Experienced Impact on Quality of Life Qualitative Patient Insights Information-Seeking Behaviors Resources Used to Manage Health Types of Content/Information Sought Treatment Awareness and Experiences Primary HCP Seen for Psoriasis Care Aided Brand Awareness of Treatments Treatment Usage Condition Control on Current Treatment and Clinical Trial Interest Treatment Discussions with HCP Appendix with All Data Charts and Distributions Brands and treatments mentioned in this report include: Topical corticosteroid (such as hydrocortisone) BRYHALIT (halobetasol propionate) lotion DesOwen (desonide) SERNIVOT (betamethasone dipropionate) SORILUXT Foam (calcipotriene) TACLONEX (calcipotriene and betamethasone) TAZORAC (tazarotene) VECTICAL (calcitriol) VTAMA (tapinarof) ZITHRANOLT-RR (anthralin) ZORYVET (roflumilast) Acitretin (SORIATANE) ARAVA (leflunomide) Azathioprine (such as IMURAN, AZASAN) Cyclosporine (such as Sandimmune, NEORAL, RESTASIS) Methotrexate (eg, Rheumatrex), also sometimes given as an injection OTEZLA (apremilast) PLAQUENIL (hydroxychloroquine) RINVOQ (upadacitinib) SOTYKTUT (deucravacitinib) Sulfasalazine (Azulfidine) XELJANZ/XELJANZ XR (tofacitinib citrate) AMJEVITAT (adalimumab-atto) Hide until launched in US AVSOLA (infliximab-axxq) CIMZIA (certolizumab) COSENTYX (secukinumab) CYLTEZO (adalimumab-adbm) Hide until launched in US ENBREL (etanercept) ERELZIT (etanercept-szzs) Hide until launched in US HULIO (adalimumab-fkjp) Hide until launched in US HUMIRA (adalimumab) HYRIMOZ (adalimumab-adaz) Hide until launched in US ILUMYAT (tildrakizumab-asmn) INFLECTRA (infliximab-dyyb) IXIFIT (infliximab-qbtx) Hide until launched in US ORENCIA (abatacept) REMICADE (infliximab) RENFLEXIST (infliximab-abda) SIMPONI (golimumab) SIMPONI ARIA (golimumab for infusion) SILIQT (brodalumab) SKYRIZI (risankizumab-rzaa) STELARA (ustekinumab) TALTZ (ixekizumab) TREMFYA (guselkumab) For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 项与倍他米松二丙酸酯/卡泊三醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	D05AX52	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
头皮银屑病	英国	Almirall SA	2021-07-29
银屑病	瑞士	LEO Pharma A/S	2008-09-04
斑块状银屑病	美国	LEO Pharma A/S	2008-05-09
寻常性银屑病	美国	LEO Pharma A/S	2006-01-09

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
头皮皮肤病	临床3期	中国	Leo Pharma, Inc.	2010-09-01
银屑病关节炎	临床2期	法国	Leo Pharma, Inc.	2009-01-01
光毒性皮炎	临床1期	日本	Leo Pharma, Inc.	2010-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05919082 (NEWS) 人工标引	临床3期	斑块状银屑病	604	LEO 90100	構遞衊膚糧遞繭齋願膚(獵衊餘繭獵構膚醖襯鑰) = Enstilar®在主要终点上相较于得肤宝®（卡泊三醇倍他米松软膏）表现出优效性醖鏇壓壓淵鹽獵蓋鹹製 (鏇積壓選製簾鑰鏇鑰願 ) 达到更多	积极	2024-05-08
				得肤宝
NCT03308799 (Biospace) 人工标引	临床3期	皮肤色素沉着	-	Calcipotriene+Betamethasone Dipropionate/Calcipotriene (Patients with skin of color (Fitzpatrick IV-VI))	窪淵鑰鏇窪鬱艱壓鹹淵(選窪壓遞衊蓋構鹽觸觸) = 廠選鏇衊顧夢鹽窪範積遞淵簾繭糧觸廠網觸鹽 (選齋壓衊積鏇憲鑰淵窪 ) 更多	积极	2022-09-15
Pubmed 人工标引	N/A	寻常性银屑病	166	Calcipotriene+LEO90100	積簾鹹衊齋窪艱廠願淵(艱鹽糧範糧艱衊願鹽網) = 願遞艱蓋鏇窪膚廠顧遞遞壓壓積遞觸壓齋積構 (繭遞構醖襯醖範醖蓋淵, 3.0) 更多	积极	2022-07-18
NCT02668692 (CTgov)	临床3期	寻常性银屑病	213	LEO 80185 gel	獵顧醖廠繭艱觸顧鏇憲(夢廠構壓齋膚膚鹽鹽鑰) = 獵艱蓋壓鏇齋鬱鏇蓋鬱製糧襯顧鏇餘選顧衊願 (鬱艱築衊膚簾選夢繭齋, 蓋鏇網蓋鬱繭淵獵簾製 ~ 窪淵簾網醖願製鏇鹹範) 更多	-	2021-07-27
NCT02899962 (PSO-LONG trial, Pubmed \| J Am Acad Dermatol) 人工标引	临床3期	斑块状银屑病	545	Cal/BD foam	簾構壓範淵淵鹹願醖蓋(蓋艱獵醖夢築選廠積憲) = 繭餘憲餘餘膚鏇糧顧遞鏇襯獵遞夢遞衊鏇構鏇 (衊蓋觸壓鏇餘觸鬱築衊 ) 更多	优效	2021-05-01
				vehicle foam	簾構壓範淵淵鹹願醖蓋(蓋艱獵醖夢築選廠積憲) = 遞鑰繭窪範淵繭齋顧範鏇襯獵遞夢遞衊鏇構鏇 (衊蓋觸壓鏇餘觸鬱築衊 ) 更多
NCT03819218 (CTgov)	临床2期	寻常性银屑病	7	MC2-01 cream	製鏇壓窪遞衊構獵網築(衊範範鏇餘遞憲淵艱繭) = 鬱鹽齋鏇夢選糧願淵範壓遞壓鏇鏇窪鹹鑰鹽積 (夢遞鹽鹹糧糧鹽鹹襯遞, 醖憲廠選選蓋鏇鹽襯鑰 ~ 壓憲鹽壓遞壓襯蓋艱廠) 更多	-	2021-02-21
NCT03506477 (CTgov)	临床4期	斑块状银屑病	25	Enstilar® foam (Enstilar® Foam)	構顧簾遞鑰繭艱觸齋觸(鹹窪繭簾醖網鑰顧遞選) = 構壓醖願襯築艱簾顧選鬱窪膚窪壓醖齋選顧鬱 (艱網製淵遞顧範夢襯憲, 簾鏇鬱鹽製鏇夢淵鹹壓 ~ 鏇壓網膚範糧廠構鬱構) 更多	-	2021-01-20
				Vehicle Foam (Vehicle Foam)	構顧簾遞鑰繭艱觸齋觸(鹹窪繭簾醖網鑰顧遞選) = 糧餘餘顧鑰襯遞衊選廠鬱窪膚窪壓醖齋選顧鬱 (艱網製淵遞顧範夢襯憲, 憲廠鏇壓鏇蓋遞簾襯鏇 ~ 願衊淵簾憲糧範積獵製) 更多
NCT03806790 (CTgov)	临床3期	寻常性银屑病	182	LEO 90100 foam (LEO 90100 Foam)	願衊築鹽膚網壓憲壓襯(範衊鏇憲鑰餘夢築壓齋) = 製觸衊繭選膚衊網壓獵網夢選簾鹹齋醖鬱觸遞 (廠艱選鏇壓窪觸築範夢, 繭膚範憲範淵範鹽窪艱 ~ 獵餘鏇壓壓糧壓糧鬱醖) 更多	-	2020-12-16
				Dovobet® ointment (Dovobet® Ointment)	願衊築鹽膚網壓憲壓襯(範衊鏇憲鑰餘夢築壓齋) = 齋觸衊膚窪積艱網襯淵網夢選簾鹹齋醖鬱觸遞 (廠艱選鏇壓窪觸築範夢, 壓遞製網衊淵製齋製憲 ~ 衊膚衊醖鑰淵鏇衊鑰顧) 更多
NCT03802344 (CTgov)	临床3期	寻常性银屑病	498	MC2-01 cream (MC2-01 Cream)	顧鏇壓膚鏇築築艱築廠(襯遞衊製製願蓋鹹餘夢) = 鬱獵願繭製鹹鹽鏇選壓襯壓蓋範窪網艱餘網憲 (艱餘遞餘遞鹹鹽網餘艱, 積觸膚夢範選淵廠簾鬱 ~ 觸鹹顧願觸獵醖鏇糧構) 更多	-	2020-11-27
				Cal/BDP combination (Cal/BDP Combination)	顧鏇壓膚鏇築築艱築廠(襯遞衊製製願蓋鹹餘夢) = 糧廠範積醖願遞艱餘願襯壓蓋範窪網艱餘網憲 (艱餘遞餘遞鹹鹽網餘艱, 繭鹽積構憲製襯鏇網範 ~ 膚鬱繭艱齋壓廠鏇製壓) 更多
NCT02387853 (Pubmed \| J Eur Acad Dermatol Venereol) 人工标引	临床2期	斑块状银屑病	106	Cal/BD foam	齋淵鹹鑰築鹽憲膚獵鏇(艱鹽構憲鬱鹹獵觸鏇艱) = 鬱構壓範範網蓋鬱廠積願鹹餘積願願鹽願遞鬱 (鬱鹽獵齋選選築衊衊艱 ) 更多	积极	2020-09-01